Literature DB >> 31907644

Risk of perioperative bleeding complications in rhegmatogenous retinal detachment surgery: a retrospective single-center study.

Sebastian Bemme1, Peer Lauermann2, Nina Antonia Striebe2, Mohammed Haitham Khattab2, Johannes Affeldt3, Josep Callizo2, Thomas Bertelmann2, Sebastian Pfeiffer4, Hans Hoerauf2, Nicolas Feltgen2.   

Abstract

PURPOSE: The goal of this study was to analyze the incidence of perioperative bleeding complications in rhegmatogenous retinal detachment. The handling of perioperative anticoagulation during vitreoretinal surgery remains controversial, since the risk of bleeding complications by its continuation has to be balanced against the risk of progression of retinal detachment and the risk of thromboembolic events when anticoagulation is interrupted. Nevertheless, only few studies have investigated the risk of perioperative bleeding complications in an emergency such as retinal detachment surgery.
METHODS: We therefore examined the rate of all perioperative hemorrhages and separately the rate of only severe bleedings during vitrectomy, scleral buckling with or without drainage of subretinal fluid (SRD), or combined procedures due to retinal detachment in patients undergoing different types of perioperative anticoagulation including acetylsalicylic acetate (ASA), clopidogrel, heparin, low molecular weight heparin, and phenprocoumon.
RESULTS: This retrospective single-center study included 893 patients with primary rhegmatogenous retinal detachment, n = 192 on anticoagulation and n = 701 serving as control without anticoagulation. Our analysis revealed no significantly increased rate of perioperative hemorrhages under anticoagulation with ASA 100 mg (all, 11.4%; severe, 5.0%) or phenprocoumon (all, 11.6%; severe, 2.3%) compared with controls (all, 13.0%; severe, 5.4%). However, frequencies of bleeding complications varied markedly regarding the type of surgical procedure: Scleral buckling plus SRD showed the highest rates of hemorrhages (all, 18.9%; severe, 9.1%) with significant difference (P < 0.001) compared with scleral buckling without SRD (all, 3.8%; severe, 0.6%) and vitrectomy (all, 9.2%; severe, 1.5%), respectively. Furthermore, subretinal bleeding was the most common type of perioperative hemorrhage.
CONCLUSIONS: The data suggest not to stop ASA therapy prior to vitreoretinal surgery. Furthermore, we found no evidence of an increased risk for perioperative bleedings in patients under anticoagulation with vitamin-k antagonists with an INR within the sub-therapeutic range. SRD during scleral buckling procedure should be avoided as possible and regardless of any type of anticoagulation.

Entities:  

Keywords:  Anticoagulation; Buckling surgery; Hemorrhage; Retinal bleeding; Retinal detachment; Vitrectomy

Year:  2020        PMID: 31907644     DOI: 10.1007/s00417-019-04554-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  Warfarin in vitreoretinal surgery: a case controlled series.

Authors:  Aman Chandra; Fiona Jazayeri; Tom H Williamson
Journal:  Br J Ophthalmol       Date:  2010-11-11       Impact factor: 4.638

2.  [Recommendation for the implementation of intravitreal injections--statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].

Authors:  G B Jaissle; P Szurman; K U Bartz-Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  2005-05       Impact factor: 0.700

3.  Sub-Tenon's anesthesia with aspirin, warfarin, and clopidogrel.

Authors:  Nishant Kumar; Sharmila Jivan; Peter Thomas; Hamish McLure
Journal:  J Cataract Refract Surg       Date:  2006-06       Impact factor: 3.351

Review 4.  Antiplatelets and anticoagulants in vitreoretinal surgery, with a special emphasis on novel anticoagulants: a national survey and review.

Authors:  Rupa Patel; Stephen Charles; Assad Jalil
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-04-18       Impact factor: 3.117

5.  Comparison of hemorrhagic complications of warfarin and clopidogrel bisulfate in 25-gauge vitrectomy versus a control group.

Authors:  John O Mason; Shelly R Gupta; Christopher J Compton; Paul A Frederick; Michael G Neimkin; Mark L Hill; Mila J Heersink; Rachel S Vail; Milton F White; Richard M Feist; Martin L Thomley; Michael A Albert
Journal:  Ophthalmology       Date:  2010-09-29       Impact factor: 12.079

6.  Maintenance of anticoagulant and antiplatelet agents for patients undergoing peribulbar anesthesia and vitreoretinal surgery.

Authors:  Marie Passemard; Philippe Koehrer; André Juniot; Alain M Bron; Catherine Creuzot-Garcher
Journal:  Retina       Date:  2012-10       Impact factor: 4.256

7.  Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy.

Authors:  Mohammed K Khuthaila; Jason Hsu; Allen Chiang; Francis Char DeCroos; Eugene A Milder; Vikram Setlur; Sunir J Garg; Marc J Spirn
Journal:  Am J Ophthalmol       Date:  2013-01-11       Impact factor: 5.258

8.  The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  James D Douketis; Peter B Berger; Andrew S Dunn; Amir K Jaffer; Alex C Spyropoulos; Richard C Becker; Jack Ansell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 9.  [Platelet aggregation inhibitors and anticoagulants during ophthalmic interventions].

Authors:  N Feltgen; H Hoerauf; W Noske; A Hager; J Koscielny
Journal:  Ophthalmologe       Date:  2016-12       Impact factor: 1.059

10.  Stopping vs. Continuing Aspirin before Coronary Artery Surgery.

Authors:  Paul S Myles; Julian A Smith; Andrew Forbes; Brendan Silbert; Mohandas Jayarajah; Thomas Painter; D James Cooper; Silvana Marasco; John McNeil; Jean S Bussières; Sophie Wallace
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

View more
  2 in total

1.  Risk Factors for Severe Bleeding Complications in Glaucoma Surgery and the Role of Antiplatelet or Anticoagulant Agents.

Authors:  Peer Lauermann; Anthea Klingelhöfer; Dorothee Mielke; Dirk Bahlmann; Hans Hoerauf; Juergen Koscielny; Christoph Sucker; Nicolas Feltgen; Christian van Oterendorp
Journal:  Clin Ophthalmol       Date:  2022-04-22

2.  [Anticoagulation and platelet aggregation inhibition : What needs to be considered in the ophthalmological practice].

Authors:  Oliver Zeitz; Laura Wernecke; Nicolas Feltgen; Christoph Sucker; Jürgen Koscielny; Thomas Dörner
Journal:  Ophthalmologe       Date:  2021-07-19       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.